Terms: = Endocrine gland cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Clinical Outcome
75 results:
1. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and clinical outcome in Pancreatic cancer.
Blise KE; Sivagnanam S; Betts CB; Betre K; Kirchberger N; Tate BJ; Furth EE; Dias Costa A; Nowak JA; Wolpin BM; Vonderheide RH; Goecks J; Coussens LM; Byrne KT
Cancer Immunol Res; 2024 May; 12(5):544-558. PubMed ID: 38381401
[TBL] [Abstract] [Full Text] [Related]
2. A Lactic Acid Metabolism-Related Gene Signature for Predicting clinical outcome and Tumor Microenvironmental Status in Patients with Hepatocellular Carcinoma.
Zhou Z; Wu B; Chen J; Shen Y; Wang J; Chen X; Fei F; Zhu M
Nutr Cancer; 2024; 76(3):279-295. PubMed ID: 38226887
[TBL] [Abstract] [Full Text] [Related]
3. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance.
Chen L; Gao W; Lin L; Sha C; Li T; Chen Q; Wei H; Yang M; Xing J; Zhang M; Zhao S; Xu W; Li Y; Long L; Zhu X
J Ovarian Res; 2023 Sep; 16(1):186. PubMed ID: 37674251
[TBL] [Abstract] [Full Text] [Related]
6. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma.
Ma W; Mei P
World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196
[TBL] [Abstract] [Full Text] [Related]
7. Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/AKT activation and tumorigenesis of pancreatic adenocarcinoma.
Xu Z; Liu Y; Pan Z; Qin L
Histol Histopathol; 2024 Feb; 39(2):263-277. PubMed ID: 37232506
[TBL] [Abstract] [Full Text] [Related]
8. NSD3, a member of nuclear receptor-binding set domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract] [Full Text] [Related]
9. VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer.
Li Y; Zhang J; Cai Y; Liu H; Yang W; Xu Y; Huang M
Biochem Biophys Res Commun; 2023 May; 658():107-115. PubMed ID: 37030064
[TBL] [Abstract] [Full Text] [Related]
10. Overexpression of LILRA2 indicated poor prognosis of ovarian carcinoma: A new potential biomarker and therapeutic target.
Zhang Y; Zhang L; Zhao Y; Wang S; Feng L
Taiwan J Obstet Gynecol; 2023 Jan; 62(1):77-88. PubMed ID: 36720556
[TBL] [Abstract] [Full Text] [Related]
11. MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients.
Wang G; Miao C; Mo L; Kahlert UD; Wu J; Ou M; Huang R; Feng R; Pang W; Shi W
Front Immunol; 2022; 13():1048503. PubMed ID: 36582246
[TBL] [Abstract] [Full Text] [Related]
12. Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma.
Gu P; Zeng Y; Ma W; Zhang W; Liu Y; Guo F; Ruan X; Chi J; Zheng X; Gao M
Front Endocrinol (Lausanne); 2022; 13():1008301. PubMed ID: 36353231
[TBL] [Abstract] [Full Text] [Related]
13. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.
Gao J; Zhao Z; Zhang H; Huang S; Xu M; Pan H
Cancer Immunol Immunother; 2023 May; 72(5):1121-1138. PubMed ID: 36336725
[TBL] [Abstract] [Full Text] [Related]
14. cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer.
Yu S; Yang R; Xu T; Li X; Wu S; Zhang J
Gynecol Oncol; 2022 Nov; 167(2):342-353. PubMed ID: 36114029
[TBL] [Abstract] [Full Text] [Related]
15. [An "a la carte" treatment for patients with pancreatic adenocarcinoma].
Iovanna J; Dusetti N
Medicina (B Aires); 2022; 82(4):571-573. PubMed ID: 35904914
[TBL] [Abstract] [Full Text] [Related]
16. Integrative clinical, Radiological, and Molecular Analysis for Predicting Remission and Recurrence of Cushing Disease.
Moreno-Moreno P; Ibáñez-Costa A; Venegas-Moreno E; Fuentes-Fayos AC; Alhambra-Expósito MR; Fajardo-Montañana C; García-Martínez A; Dios E; Vázquez-Borrego MC; Remón-Ruiz P; Cámara R; Lamas C; Carlos Padillo-Cuenca J; Solivera J; Cano DA; Gahete MD; Herrera-Martínez AD; Picó A; Soto-Moreno A; Gálvez-Moreno MÁ; Castaño JP; Luque RM
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2938-e2951. PubMed ID: 35312002
[TBL] [Abstract] [Full Text] [Related]
17. Cutoff Age Between Pediatric and Adult Thyroid Differentiated cancer: Is 18 Years Old Appropriate?
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Matsuzu K; Suzuki A; Tomoda C; Hames KY; Akaishi J; Masaki C; Yoshioka K; Ito K
Thyroid; 2022 Feb; 32(2):145-152. PubMed ID: 34549602
[No Abstract] [Full Text] [Related]
18. Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
Tamura R; Yoshihara K; Matsuo K; Yachida N; Miyoshi A; Takahashi K; Sugino K; Yamaguchi M; Mori Y; Suda K; Ishiguro T; Okuda S; Motoyama T; Nakaoka H; Kikuchi A; Ueda Y; Inoue I; Enomoto T
Gynecol Oncol; 2021 Nov; 163(2):327-333. PubMed ID: 34452748
[TBL] [Abstract] [Full Text] [Related]
19. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma.
Wen C; Deng X; Ren D; Song X; Chen H; Wang J; Jin J; Cheng D; Xu Z; Zhang J; Xie J; Qi W; Gu J; Peng C; Chen D; Chen S; Shen B; Zhan Q
Cancer Med; 2020 Oct; 9(20):7626-7636. PubMed ID: 32862515
[TBL] [Abstract] [Full Text] [Related]
20. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H; Hasegawa K; Oda K; Yamamoto S; Asada K; Karasaki T; Yabuno A; Nishijima A; Nejo T; Kobayashi Y; Sato S; Ikeda Y; Miyai M; Takahashi Y; Yamaguchi R; Fujiwara K; Aburatani H; Kakimi K
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461346
[TBL] [Abstract] [Full Text] [Related]
[Next]
